• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PHARMAC promotes competition to improving patient access to high-cost medicines

PHARMAC promotes competition to improving patient access to high-cost medicines

April 10, 2014
CenterWatch Staff

PHARMAC has announced its intention to test out a contestable fund for high-cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014. Promoting competition among suppliers could be the key to improving patients’ access to high-cost medicines for rare disorders, said chief executive Steffan Crausaz. The fund is a response to concerns about access to these medicines that PHARMAC has been hearing from patients through forums and consultations in recent months.

“We’ve listened closely to these views, and thought about them carefully. Our thinking leads us to the view that the core problem is a lack of competition,” said Crausaz. “We know competition leads to lower prices, and that’s an area where PHARMAC has an established track record. Our activities in promoting competition enable New Zealand to achieve some of the lowest prices for medicines in the world. We think that by promoting competition among suppliers, prices will reduce and as a result, patients will get funded access to them. Ultimately, that’s what this fund is about.

“Pharmaceutical suppliers tell us one of their main motivators is providing patients with access to their products,” he said. “That’s something we certainly want to see, and I hope the industry takes this opportunity to help us find a way to make these medicines more available to patients.”

Crausaz said the new approach is possible within PHARMAC’s current operating framework, and would still involve PHARMAC seeking to get the best health outcomes for patients from the available funding for pharmaceuticals.

“PHARMAC will continue to look for the best health outcomes for patients, and the best value investments. The approach we intend to use will be consistent with the PHARMAC model and, importantly, still will enable us to continue to fund other new medicines for conditions that aren’t rare,” said Crausaz.

PHARMAC has published a discussion paper on its web site and is inviting comments from the public and industry on the contestable fund. These comments would help iron out some details of how the fund would operate.

Crausaz said up to $5 million per year may be available, through funding that already has been budgeted but is not likely to be used for the $8 million exceptions policy. Because this funding already is budgeted, it won't limit PHARMAC's ability to fund other treatments for less rare conditions.

Should PHARMAC request commercial proposals by the end of 2014, funding could begin in early 2015.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing